GI
SYRE icon

GAMMA Investing’s Spyre Therapeutics SYRE Stock Holding History

GAMMA Investing’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Buy
663
+140
+27% +$10.2K ﹤0.01% 2192
2026
Q1 		$26.4K Buy
523
+193
+58% +$7.28K ﹤0.01% 2571
2025
Q4 		$10.8K Buy
330
+122
+59% +$3.19K ﹤0.01% 2939
2025
Q3 		$3.49K Buy
208
+34
+20% +$554 ﹤0.01% 3305
2025
Q2 		$2.6K Sell
174
-96
-36% -$1.42K ﹤0.01% 3327
2025
Q1 		$4.36K Buy
+270
New +$5.62K ﹤0.01% 3138
2024
Q4 		– Sell
-5
Closed -$147 – 3825
2024
Q3 		$147 Buy
+5
New +$139 ﹤0.01% 3541

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GAMMA Investing's SYRE Position: Q2 2026 in Review

GAMMA Investing increased its Spyre Therapeutics (SYRE) stake by 27% in Q2 2026, buying an estimated $10.2K and bringing the position to 663 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

GAMMA Investing first reported a position in SYRE in Q3 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • GAMMA Investing held 663 shares of Spyre Therapeutics worth $58.9K as of Q2 2026.
  • GAMMA Investing bought 140 Spyre Therapeutics shares in Q2 2026, an estimated $10.2K.
  • Spyre Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2192 holding.
  • GAMMA Investing first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.